Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tests a new drug called TQB3616 combined with standard hormone therapy to see if it can stop breast cancer from returning in people with HR-positive, HER2-negative breast cancer. About 1,946 women who have had surgery to remove their cancer will take either the new dru…

This phase 3 trial tests whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can delay cancer growth in people with HR-positive, HER2-negative advanced breast cancer who have not received prior treatment. About 432 participants will be randomly …

This study tests whether adding an experimental tablet (TQ-A3334) to standard antiviral pills can better control chronic hepatitis B virus. About 116 adults with long-term infection will receive either the new drug or a placebo, plus their usual medication. The main goal is to se…

This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…

This study tests an experimental tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't improved with steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The go…

This study tests whether a new drug called anlotinib, combined with chemotherapy, works better than the current standard treatment for people with a specific type of advanced colorectal cancer (RAS/BRAF wild-type). About 748 participants will receive either anlotinib plus chemo o…

This phase 2 study tests a new drug (TQB3616) combined with hormone therapy for people with a common type of breast cancer (HR-positive, HER2-negative) that has returned or spread and no longer responds to a standard class of drugs called CDK4/6 inhibitors. The trial enrolls 33 a…

This study tests a new inhaled powder called TQC3721 in 195 people with moderate to severe COPD. The goal is to see if it improves lung function (measured by how much air you can exhale in one second) over four weeks compared to a placebo. Participants must be 40-80 years old and…